The Food and Drug Administration has approved betrixaban for preventing blood clotting among patients with deep vein thrombosis. The oral treatment is the first extended duration treatment for hospitalized acutely ill patients.
The Food and Drug Administration has approved betrixaban for preventing blood clotting among patients with deep vein thrombosis. The oral treatment is the first extended duration treatment for hospitalized acutely ill patients.
Share this Article
Recommended